Stability Issues Unique To Liquid Injectables And How To Avoid Them

Developing a liquid injectable introduces a complex stability landscape that demands proactive, science‑driven decision‑making from the earliest development stages. Unlike solid forms, liquid formulations continuously expose molecules to degradation pathways such as oxidation, hydrolysis, and structural changes, which can silently compromise potency and safety. Biologics and peptides are particularly vulnerable, with risks of aggregation, unfolding, or sensitivity to interfaces like glass or silicone oil.

Packaging choices—including vial materials, stoppers, and prefilled syringes—further influence degradation, making early compatibility studies essential. Temperature also plays a critical role, as fluctuations during shipping and handling can accelerate chemical or physical instabilities. To avoid costly reformulation, manufacturing delays, or regulatory setbacks, biotechs must implement a robust preformulation strategy supported by precise excipient selection, gentle manufacturing processes, and realistic stability studies.

By addressing risks early and comprehensively, development teams can safeguard product quality and ensure reliable performance from lab to patient.